Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Cytisinicline

  • Home
  • Cytisinicline
Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials
Posted innews Psychiatry

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

Posted by MedXY By MedXY 09/25/2025
Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.
Read More
Cytisinicline’s Promise in Smoking Cessation: Insights from the ORCA Phase 3 Replication Trial
Posted inClinical Updates news Public Health Respiratory Specialties

Cytisinicline’s Promise in Smoking Cessation: Insights from the ORCA Phase 3 Replication Trial

Posted by MedXY By MedXY 08/25/2025
The ORCA-3 trial confirms cytisinicline's efficacy and safety for smoking cessation at 6 and 12 weeks, showing sustained abstinence and reduced nicotine craving up to 24 weeks.
Read More
  • Post-infection Gut-Brain Disorders Affect About 1 in 10 People With DGBI Worldwide, With Distinct Psychological and Regional Patterns
  • PRDM9 Deficiency Identifies a Predominant Molecular Subgroup in Sporadic Hirschsprung Disease and Enables Blood-based Risk Stratification
  • Ultra-Early Remote Ischemic Postconditioning After Thrombectomy Appears Safe but Does Not Improve 90-Day Stroke Recovery
  • Postmenopausal Migraine Signals Higher Ischemic Stroke Risk, Not Hemorrhagic Stroke, in the Women’s Health Initiative
  • Hypertension-Related High-Risk Features May Identify Which Patients With Cryptogenic Stroke Benefit From Apixaban Instead of Aspirin
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in